
Oxford Cannabinoid Technologies Holdings Plc – LSE:OCTP.L
Oxford Cannabinoid Technologies Holdings stock price today
Oxford Cannabinoid Technologies Holdings stock price monthly change
Oxford Cannabinoid Technologies Holdings stock price quarterly change
Oxford Cannabinoid Technologies Holdings stock price yearly change
Oxford Cannabinoid Technologies Holdings key metrics
Market Cap | 1.25M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | -2.40M |
Income | -7.94M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOxford Cannabinoid Technologies Holdings stock price history
Oxford Cannabinoid Technologies Holdings stock forecast
Oxford Cannabinoid Technologies Holdings financial statements
Nov 2021 | 0 | -1.01K | |
---|---|---|---|
Oct 2022 | 0 | -3.70M | |
Apr 2023 | 0 | -2.23M | |
Oct 2023 | 0 | -2M |
Nov 2021 | 12960638 | 573.60K | 4.43% |
---|---|---|---|
Jul 2022 | 7426 | 1.27K | 17.22% |
Oct 2022 | 7426436 | 1.27M | 17.22% |
Oct 2023 | 2790000 | 840K | 30.11% |
Nov 2021 | -2.58K | 35 | -67 |
---|---|---|---|
Oct 2022 | -4.23K | 0 | 0 |
Apr 2023 | -2.63K | 0 | 0 |
Oct 2023 | -1.16K | 0 | 0 |
Oxford Cannabinoid Technologies Holdings alternative data
Aug 2023 | 7 |
---|---|
Sep 2023 | 7 |
Oct 2023 | 7 |
Nov 2023 | 7 |
Dec 2023 | 7 |
Jan 2024 | 7 |
Feb 2024 | 7 |
Mar 2024 | 7 |
Apr 2024 | 7 |
May 2024 | 7 |
Jun 2024 | 7 |
Jul 2024 | 7 |
Oxford Cannabinoid Technologies Holdings other data
-
What's the price of Oxford Cannabinoid Technologies Holdings stock today?
One share of Oxford Cannabinoid Technologies Holdings stock can currently be purchased for approximately $2.33.
-
When is Oxford Cannabinoid Technologies Holdings's next earnings date?
Unfortunately, Oxford Cannabinoid Technologies Holdings's (OCTP.L) next earnings date is currently unknown.
-
Does Oxford Cannabinoid Technologies Holdings pay dividends?
No, Oxford Cannabinoid Technologies Holdings does not pay dividends.
-
How much money does Oxford Cannabinoid Technologies Holdings make?
Oxford Cannabinoid Technologies Holdings has a market capitalization of 1.25M.
-
What is Oxford Cannabinoid Technologies Holdings's stock symbol?
Oxford Cannabinoid Technologies Holdings Plc is traded on the LSE under the ticker symbol "OCTP.L".
-
What is Oxford Cannabinoid Technologies Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oxford Cannabinoid Technologies Holdings?
Shares of Oxford Cannabinoid Technologies Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Oxford Cannabinoid Technologies Holdings have?
As Jul 2024, Oxford Cannabinoid Technologies Holdings employs 7 workers.
-
When Oxford Cannabinoid Technologies Holdings went public?
Oxford Cannabinoid Technologies Holdings Plc is publicly traded company for more then 4 years since IPO on 21 May 2021.
-
What is Oxford Cannabinoid Technologies Holdings's official website?
The official website for Oxford Cannabinoid Technologies Holdings is oxcantech.com.
-
How can i contact Oxford Cannabinoid Technologies Holdings?
Oxford Cannabinoid Technologies Holdings can be reached via phone at +44 20 3034 2820.
Oxford Cannabinoid Technologies Holdings company profile:

Oxford Cannabinoid Technologies Holdings Plc
oxcantech.comLSE
7
Biotechnology
Healthcare
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
London, W1S 2PZ
:
ISIN: GB00BMVMRB86
: